FAQ on Lantern Pharma Inc. (NASDAQ: LTRN) and Its AI-Driven Oncology Drug Development
Summary
Lantern Pharma Inc. is a clinical-stage biotechnology company using AI and machine learning to revolutionize oncology drug development, with a focus on precision cancer therapies through its RADR(R) platform.
What is Lantern Pharma Inc.?
Lantern Pharma Inc. is a clinical-stage biotechnology company that leverages artificial intelligence and machine learning to transform the development of precision cancer therapies, utilizing its proprietary RADR(R) platform.
What is the RADR(R) platform?
The RADR(R) platform is Lantern Pharma’s proprietary AI and machine learning system that integrates over 200 billion oncology-specific data points and a library of 200+ advanced ML algorithms to accelerate oncology drug discovery and development.
What are Lantern Pharma’s lead drug candidates targeting?
Lantern Pharma has three lead drug candidates in clinical development targeting non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and non-Hodgkin’s lymphoma (NHL), with Starlight Therapeutics extending its focus to brain and CNS cancers.
What FDA designations has Lantern Pharma received?
Lantern Pharma has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, which enhances regulatory pathways for its drug candidates.
How does Lantern Pharma’s approach compare to traditional drug development?
Lantern Pharma’s AI-driven approach has advanced drug programs from initial AI insights to first-in-human clinical trials in 2-3 years at approximately $2.5 million per program, significantly reducing the time and cost compared to traditional methods.
Where can I find more information about Lantern Pharma Inc.?
More information about Lantern Pharma Inc. is available in the company’s newsroom at https://ibn.fm/LTRN and through the full article at https://ibn.fm/s1B45.
Who is behind AINewsWire?
AINewsWire is a specialized communications platform focusing on AI advancements, part of the Dynamic Brand Portfolio within the InvestorBrandNetwork (IBN), which provides extensive distribution and enhancement services for press releases and articles.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 99508